Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 58.7% in October

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 160,100 shares, a growth of 58.7% from the October 15th total of 100,900 shares. Based on an average daily trading volume, of 117,900 shares, the short-interest ratio is presently 1.4 days.

Institutional Trading of Enlivex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of Enlivex Therapeutics in the 2nd quarter valued at about $35,000. Sigma Investment Counselors Inc. purchased a new position in shares of Enlivex Therapeutics during the 3rd quarter valued at about $50,000. Finally, Armistice Capital LLC purchased a new position in shares of Enlivex Therapeutics during the 2nd quarter valued at about $2,415,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Trading Down 0.9 %

ENLV stock opened at $1.07 on Friday. The stock’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $1.39. Enlivex Therapeutics has a 1-year low of $1.01 and a 1-year high of $4.59. The stock has a market cap of $22.91 million, a P/E ratio of -0.91 and a beta of 1.11.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings results on Friday, August 30th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. As a group, analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Enlivex Therapeutics in a report on Friday, September 27th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.